Quote:The Big "Pharma" meet that was scheduled with Cytodyn has been on the books since June. Despite everyone's hope's with various indications like TnBC, colorectal, NASH, the 1 Big pharma in particular does not have faith in those indications making it past Phase 2. Even if Leronlimab works as described in HIV, as far as antagonizing CCR5 receptors, the fact that certain cancers have specificity toward CCR5 receptors doesn't mean cancer cells stop metastasizing. Cancers develop when the mutated cells are prohibited from continuing through the cell cycle. Even with correlation of metastasis to the CCR5 receptor, the cancers AT BEST CASE SCENARIO, will allow for a longer period of remission, before the cancer reemerges. THERE IS NOT 1 PATHWAY for cancer. It would be nice if life was that simple, by blocking 1 pathway and everything is solved.
From my own research this could be true with BPs assumptions, if they do just license hiv, we need to ensure the get zero cancer sales. Licensing hiv and focusing on cancer for the right price would be fantastic in my opinion, if they can ensure that.
Quote:THERE IS NOT 1 PATHWAY for cancer.
Several BPs are testing ccr5 now. They have tried numerous pathways with cancer, many failing due to the overlap with chemokines , receptors. I could see their skepticism. Blocking one, it still works through another pathway, which is why most cancer trials end in failure.
But ccr5 has some unique MOAs, with no other pathway, no overlap. So blocking ccr5 will not 'stop all cancer metastasis', but it will reduce those unique pathways, in my opinion, reducing cancer to the other pathways which have a higher life expectancy. One such is metastatic to organ, bones, brain, which the majority of metastasis death are from, I believe this is uniquely through ccr5. If the cancer spreads but not to the critical kill zones, longer overall life expectancy. The TAM switch, the bodies immune response turned off, promote cancer, kill cancer I believe is uniquely through ccr5. The dna repair of cancer cell, which is why ccr5 is overexpressed during chemo or radiation, it enables the cell to repair at a faster rate (vs non-ccr5) instead of dying, I believe is uniquely through ccr5. So I am expecting good results. In my opinion, it is the opposite, the results would be better before stage 4, or early stage4, than late stage 4.
1
